Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial)

Pulmonary Pharmacology and Therapeutics

Volumn 17, Issue 1, 2004, Pages 27-34

  Malerba, Mario ^a   Ponticiello, Antonio ^b   Radaeli, Alessandro ^a   Bensi, Giuliano ^c   Grassi, Vittorio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Boehringer Ingelheim Italia SpA   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Mucolytics; Prevention

Indexed keywords

AMBROXOL;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0344983271     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2003.08.004     Document Type: Article

References (35)

1. Mitchell R., Petty T. Chronic obstructive pulmonary disease. Mitchell R.S., Petty T.L., Shwarz M.I. Synopis for clinical pulmonary disease. 4th ed :1989;146-161 C.V. Mosby, St. Louis.
2. Hogg J.C., Macklem P.T., Thurlbeck W.M. Site and nature of airway obstruction in chronic obstructive lung disease. N Eng J Med. 278:1968;1355-1360.
3. Rogers D.F. Mucus hypersecretion in chronic obstructive pulmonary disease. Novartis Found Symp. 234:2001;65-77. discussion 77-83.
4. Puchelle E., Azhm J.M., Polu J., Sadoul P. Drug effects on visco-elasticity of mucus. Eur J Respir Dis. 61:(Suppl.):1980;195-203.
5. Braga P.C., Allegra L., Rampoldi C., Ornaghi A., Beghi G. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administartion of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration. 57:1990;353-358.
6. Long term oral acetylcysteine in chronic bronchitis. A double blind controlled study. Eur J Respir Dis. 61:(Suppl. 111):1980;93-108.
7. Boman G., Bäcker U., Larsson S., Melander B., Wåhlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organised by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 64:1983;405-415.
8. Grassi C., Morandini G.C. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharm. 9:1976;393-396.
9. Hansen N.C.G., Skriver A., Brorsen-Riis L., Basløv S., Evald T., Matbaek N., Gunnersen G., Garsdal P., Sander P., Pedersen J.Z., Ibsen T.B., Rasmussen F.V. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 88:1994;531-535.
10. Jackson I.M., Barnes J., Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study. J Int Med Res. 12:(3):1984;198-206.
11. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax. 40:(11):1985;832-835.
12. Meister R. Langzeittherapie mit Acetykcystein Retard-Tabletten bei Patienten mit chronischer bronchitis. Eine doppel-blinde-placebokontrollierte studie. Forum Prakt Allg Arzt. 25:1986;18-22.
13. Parr G.D., Huitson A. Oral fabrol (oral N-acetyl-cysteune) in chronic bronchitis. Br J Chest Dis. 81:1987;341.
14. Pela R., Calcagni A.M., Subiaco S., Isidori P., Tubaldi A., Sanguinetti C.M. N-acetylcisteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 66:1999;495-500.
15. Rasmussen J.B., Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J. 1:1988;351-355.
16. Olivieri D., Zavattini G., Tomasini G., Daniotti S., Bonsignore G., Ferrara G., Carnimeo N., Chianese R., Catena E., Marcatili S., Del Donno M., Grassi C., Pozzi E., Grassi V., Tantucci C., Lucchesi M., Schimid G., Marchioni C.F., Penitenti S., Mistretta A., Crimi N., Casali L., Cabiddu R., Donner C., Patessio A., Massei V., Sanguinetti C.M., Orlandi O., Bruna S., Serra C., Giacopelli A. Ambroxol for the prevention of chronic bronchitis exacerabations: long-term multicentre trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration. 51:(Suppl. 1):1987;42-51.
17. Guyatt G.H., Townsend M., Kazim F., Newhouse M.T. A controlled trial of ambroxol in chronic bronchitis. Chest. 4:1992;618-620.
18. Cegla U.H. Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Results of a double-blind study of 180 patients. Prax Klin Pneumol. 42:(9):1988;715-721.
19. Ericsson C.H., Juhasz J., Jonsson E., Mossberg B. Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function. Respiration. 51:(Suppl. 1):1987;33-36.
20. Allegra L., Cordaro C.I., Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteyne lysine salt monohydrate: a multicener, double blind, placebo controlled trial. Respiration. 63:1996;174-180.
21. Petty T.L. The National Mucolytic Study. Results of a randomized, double-blind, placebo controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest. 97:(1):1990;75-83.
22. Rubin B.K., Ramirez O., Ohar J. Iodinate glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest. 109:1996;348-352.
23. Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: a systematic review. BMJ. 322:2001;1271-1274.
24. Siafakas N.M., Vermeire P., Pride N.B., Paoletti P., Gibson J., Howard P., Yernault J.C., Decramer M., Higenbottam T., Postma D.S., Rees J. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 8:1995;1398-1420.
25. Pauwels R.A., Buist A.S., Ma P., Jenkins C.R., Hurd S.S. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 46:(8):2001;798-825.
26. Weiss T., Dorow P., Felix B. Effects of a beta-adrenegic drug and secretolytic agent on regional mucociliary clearance in patients with, COLD. Chest. 80:1981;881-885.
27. Olivieri D., Marsico S.A., Del Donno M. Improvement of mucociliary transport in smokers by mucolytics. Eur J Respir Dis. 66:1985;142-145.
28. Post M., Batenburg J.J., Schuurmans E.A.J.M., Oldenborg V., Van der Molen A.J., Van Golde L.M.G. The perfused rat lung as a model for studies on the formation of surfactant and the effect of ambroxol on this process. Lung. 161:1983;349-359.
29. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 152:1995;S77-S120.
30. SAS/STAT user's guide. Version 6. 4th ed :1989;SAS Institute Inc, Cary, NC.
31. Grandjean M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcsteine in chronic bronchopulmonary disease: a metha-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 22:(2):2000;209-221.
32. Stey C., Steurer J., Bachmann S., Medici T.C., Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis, a quantitative systematic review. Eur Respir J. 16:2000;253-262.
33. Rensch H., Seefeld H. Surfatant-mucus interaction. Robertson B., Van Golde L.M., Batenburg J.J. Pulmonary surfactant. 1984;203-214 Elsevier, Amsterdam.
34. Haagsman H.P., Van Golde L.M. Lung surfactant and pulmonary toxicytology. Lung. 163:1985;275-303.
35. Jarstrand C. Role of surfactant in the pulmonary defence system. Robertson B., Van Golde L.M., Batenburg J.J. Pulmonary surfactant. 1984;188-201 Elsevier, Amsterdam.